The Oncology Institute, Inc. (NASDAQ:TOI) Receives $8.20 Consensus PT from Brokerages

Shares of The Oncology Institute, Inc. (NASDAQ:TOI) have been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.40.

Several research analysts have issued reports on the company. B. Riley Financial increased their price target on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Lake Street Capital started coverage on Oncology Institute in a research report on Monday, July 6th. They set a “buy” rating and a $10.00 target price on the stock. BTIG Research increased their target price on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. Finally, Needham & Company LLC boosted their price target on shares of Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th.

Oncology Institute Stock Performance

Oncology Institute stock opened at $5.89 on Monday. The stock has a market capitalization of $582.17 million, a price-to-earnings ratio of -15.92 and a beta of 0.36. Oncology Institute has a 52-week low of $2.32 and a 52-week high of $6.11. The stock’s 50 day moving average price is $4.81 and its two-hundred day moving average price is $3.74.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.05. The company had revenue of $147.44 million during the quarter, compared to the consensus estimate of $142.10 million. On average, equities research analysts forecast that Oncology Institute will post -0.17 EPS for the current year.

Insider Activity

In related news, major shareholder Jorey Chernett bought 33,500 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $4.07 per share, for a total transaction of $136,345.00. Following the completion of the transaction, the insider directly owned 10,567,858 shares in the company, valued at approximately $43,011,182.06. The trade was a 0.32% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mohit Kaushal sold 57,286 shares of the stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $3.50, for a total value of $200,501.00. Following the sale, the director directly owned 211,016 shares in the company, valued at $738,556. This trade represents a 21.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have bought 98,500 shares of company stock valued at $426,655 and have sold 119,170 shares valued at $461,183. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Josh Arnold Investment Consultant LLC boosted its stake in Oncology Institute by 1,104.3% during the fourth quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company’s stock valued at $8,757,000 after buying an additional 2,255,559 shares during the period. Kanen Wealth Management LLC bought a new stake in Oncology Institute during the third quarter valued at approximately $6,421,000. Marshall Wace LLP bought a new position in Oncology Institute in the second quarter valued at $3,028,000. Geode Capital Management LLC boosted its holdings in shares of Oncology Institute by 231.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock worth $2,623,000 after purchasing an additional 893,696 shares in the last quarter. Finally, UBS Group AG increased its position in shares of Oncology Institute by 151.2% during the 3rd quarter. UBS Group AG now owns 1,055,862 shares of the company’s stock valued at $3,685,000 after purchasing an additional 635,489 shares during the last quarter. 36.86% of the stock is owned by institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.